Featured Research

from universities, journals, and other organizations

Protein that drives survival of gastrointestinal tumors identified

Date:
January 3, 2011
Source:
Rockefeller University
Summary:
For patients with gastrointestinal stromal tumors, or GISTs, the blockbuster cancer drug Gleevec has been a reason to hope. Since the drug's introduction, survival rates have climbed dramatically and recurrence has fallen by two-thirds. But there's a downside: over time, many patients develop resistance to the drug. Now, scientists have identified a molecule that acts as a survival factor for gastrointestinal tumors, a finding that may lead to next-generation therapies that can pick up where Gleevec leaves off.

Gut instinct. An examination of genetically modified mice which lack the gene for ETV1 (right) showed the animals have far fewer of the gastrointestinal cells that are prone to a specific type of tumor. The finding suggests that ETV1 is a survival factor for GIST cancer.
Credit: Image courtesy of Rockefeller University

For patients with gastrointestinal stromal tumors, or GISTs, the blockbuster cancer drug Gleevec has been a reason to hope. Since the drug's introduction, survival rates have climbed dramatically and recurrence has fallen by two-thirds. But there's a downside: over time, many patients develop resistance to the drug. Now, scientists at Rockefeller University and Memorial Sloan-Kettering Cancer Center have identified a molecule that acts as a survival factor for gastrointestinal tumors, a finding that may lead to next-generation therapies that can pick up where Gleevec leaves off.

Gleevec was initially approved for fighting chronic myelogenous leukemia and it targets the BCR-ABL fusion protein that causes that rare blood disease. But Gleevec also inhibits the activated KIT receptor tyrosine kinase. Scientists have known that mutations in the gene that codes for KIT are responsible for development of GISTs, as well as other cancers such as melanomas, which makes Gleevec a potent treatment for GISTs.

Ping Chi, a postdoctoral fellow in C. David Allis' Laboratory of Chromatin Biology and Epigenetics at Rockefeller and a clinical fellow at MSKCC, and in collaboration with Yu Chen in Charles Sawyers' group at MSKCC, searched for GIST-specific genes to obtain better insight on the molecular events in GIST development. She focused on a group of cells in the gastrointestinal tract called interstitial cells of Cajal, or ICCs. GISTs arise from two specific populations of ICCs, myenteric and intramuscular; it's been known that KIT is highly expressed in these two types of ICCs, and these cells have been implicated as the cells that spur GIST formation.

By analyzing patient tumor samples stored at MSKCC, Chi and colleagues found that a protein called ETV1 is expressed in all GISTs at significantly greater levels than in any other type of tumor. Using RNA interference, in which small RNAs are deployed to prevent gene expression, Chi and her colleagues blocked ETV1 in GIST cell lines. The result was a decrease in cell division and an increase in cell death, findings that indicated that GISTs require ETV1 for growth and survival.

"We've shown that ETV1 is just as important as KIT in the development of gastrointestinal stromal tumors," says Chi. The findings have far-reaching implications, she says.

"About five percent of GISTs are KIT negative by immunohistochemistry," Chi says. "Because all GISTs express ETV1, we now have a very good biomarker for diagnosing GIST."

Chi and her colleagues were also interested in determining if ETV1 is required for normal growth of ICCs. They looked at the gastrointestinal tracts of genetically modified mice lacking the gene for ETV1 and observed significant loss of only myenteric and intramuscular ICCs, providing evidence of ETV1's role as a survival factor for the ICC-GISTs lineage.

The discovery by Chi and her colleagues also means that scientists now have a new therapeutic target. In addition to the risk of developing resistance to Gleevec, the drug must be given continuously because interrupting Gleevec treatment can cause GISTs to rapidly regrow.

"Now that we know ETV1's importance in GIST formation, we need to determine how the ETV1-driven oncogenic transcriptome is regulated," Chi says. "This opens possibilities for stopping GIST development when targeting of KIT fails."

"This work represents a remarkable collaborative effort from both sides of York Avenue wherein our combined strengths in signaling, mouse modeling, transcriptional regulation and chromatin biology came together to tackle complex mechanisms of cancer pathogenesis," says Allis, who is Joy and Jack Fishman Professor. "In addition to the gain-of-function KIT mutation, our results clearly show that cellular context, likely determined by transcription factor networks and chromatin landscape, also plays critical roles in oncogenesis."


Story Source:

The above story is based on materials provided by Rockefeller University. Note: Materials may be edited for content and length.


Journal Reference:

  1. Ping Chi, Yu Chen, Lei Zhang, Xingyi Guo, John Wongvipat, Tambudzai Shamu, Jonathan A. Fletcher, Scott Dewell, Robert G. Maki, Deyou Zheng, Cristina R. Antonescu, C. David Allis, Charles L. Sawyers. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature, 2010; 467 (7317): 849 DOI: 10.1038/nature09409

Cite This Page:

Rockefeller University. "Protein that drives survival of gastrointestinal tumors identified." ScienceDaily. ScienceDaily, 3 January 2011. <www.sciencedaily.com/releases/2010/12/101230103554.htm>.
Rockefeller University. (2011, January 3). Protein that drives survival of gastrointestinal tumors identified. ScienceDaily. Retrieved October 22, 2014 from www.sciencedaily.com/releases/2010/12/101230103554.htm
Rockefeller University. "Protein that drives survival of gastrointestinal tumors identified." ScienceDaily. www.sciencedaily.com/releases/2010/12/101230103554.htm (accessed October 22, 2014).

Share This



More Health & Medicine News

Wednesday, October 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Working Mother (Oct. 22, 2014) Is your child ready? Video provided by Working Mother
Powered by NewsLook.com
U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

Newsy (Oct. 22, 2014) Now that the U.S. is restricting travel from West Africa, some are dropping questions about a travel ban and instead asking about visa bans. Video provided by Newsy
Powered by NewsLook.com
CDC Revamps Ebola Guidelines After Criticism

CDC Revamps Ebola Guidelines After Criticism

Newsy (Oct. 21, 2014) The Centers for Disease Control and Prevention have issued new protocols for healthcare workers interacting with Ebola patients. Video provided by Newsy
Powered by NewsLook.com
WHO: Ebola Vaccine Trials to Start a in January

WHO: Ebola Vaccine Trials to Start a in January

AP (Oct. 21, 2014) Tens of thousands of doses of experimental Ebola vaccines could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe in soon to start trials, the World Health Organization said Tuesday. (Oct. 21) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins